Kringle Pharma, Inc.
Kringle Pharma, Inc. (Kringle Pharma) is a privately held biotechnology company and is principally engaged in the research and development of treatments in the areas of cancer, skin diseases, nephrology and other therapeutic areas. Currently, the company focuses on discovery of hepatocyte growth factor, an intrinsic factor with an organotrophic role in the regeneration and repair of various tissues and organs. The company is also engaged in providing innovative treatments based on the development of hepatocyte growth factor for skin ulcers, acute renal failure and motor neuron diseases. Kringle Pharma also develops NK4, an antagonist of HGF and a multi-target angiogenesis inhibitor for the treatment of solid tumors in pre-clinical development stages. The company was established as a spin-off entity from the Osaka University. Kringle Pharma operates with a subsidiary Kringle Pharma Europe AB in Sweden. The company is headquartered at Toyonaka in Osaka, Japan.